Notably, we observed that SHIP2 activity is elevated in kidneys of patients with T2D receiving nonmetformin medication compared with people without diabetes and that metformin reduces the elevated activity of SHIP2 in the kidneys of patients with T2D, proposing a mechanism via which metformin acts renoprotectively. The gene discussed is INPPL1; the disease is type 2 diabetes mellitus.